PORTFOLIO

Aclaris Therapeutics (NASDAQ: ACRS) is a specialty pharmaceutical company focused on the development of novel dermatological therapies.
Apellis Pharmaceuticals (NASDAQ: APLS) is a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic compounds for autoimmune and inflammatory diseases.
Ascendis Pharma (NASDAQ: ASND) develops differentiated prodrug versions of high-value drugs. The company’s proprietary TransCon technology is used to generate product candidates that are improved versions of existing drugs, yielding more effective, lower-risk therapeutics with new patent lives.
Eiger (NASDAQ: EIGR) is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of Hepatitis. Our pipeline includes preclinical NCEs from discovery as well as repurposed clinical agents to treat Hepatitis C and Hepatitis D.
Harmony Biosciences is an innovative biopharmaceutical company dedicated to identifying, developing, and commercializing novel treatment options for patients with rare diseases.
Impel NeuroPharma is using its Precision Olfactory Delivery (POD) nasal devices to develop therapies for diseases of the brain such as migraine and Alzheimer’s.
Kala is a company developing novel therapies to treat serious eye conditions.
KalVista Pharmaceuticals (NASDAQ: KALV) is creating a new generation of small molecule protease inhibitors.
At MacuLogix® our mission is simple: To revolutionize vision care by empowering primary eye care professionals with the technology and tools needed to create an AMD Center of Excellence®.
Medeor Therapeutics is a private, late clinical stage, biotechnology company dedicated to the discovery, development, and commercialization of transformative and personalized cellular immunotherapies.
Menlo Therapeutics (NASDAQ: MNLO) is a clinical stage biopharmaceutical company focused on the treatment of chronic itch and chronic refractory cough.
Minerva Surgical is developing next-generation technology for treating excessive menstrual bleeding.
Nabriva (NASDAQ: NBRV) is an anti-infective company developing a novel therapy for Community Acquired Pneumonia.
Outpost Medicine is developing a novel therapy for overactive bladder and irritable bowel syndrome.
Poseida Therapeutics is a clinical-stage biopharmaceutical company leveraging our proprietary next-generation, non-viral gene engineering technologies to create life-saving cell therapeutics for patients with high unmet medical need.
Sierra Oncology (NASDAQ: SRRA) is a clinical stage drug development company advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer.
Soleno Therapeutics (NASDAQ: SLNO) is developing a novel treatment for patients with Prader-Willi syndrome (PWS).
Surgical Specialties is a medical device company that is marketing surgical products on a worldwide basis.
Swift Health Systems is a diverse team of bone biologists, computer scientists, engineers, designers, and orthodontists that are inspired to impact the lives of hundreds of millions of people worldwide.
Synapse BioMedical is a medical device company developing neurostimulation products. The company’s products have been approved by the FDA for patients with spinal cord injury and amyotrophic lateral sclerosis.
Tricida (NASDAQ: TCDA) is a publicly held, clinical stage, biopharmaceutical company focused on the discovery and development of non-absorbed therapies.

Privately held companies at the time of Vivo’s initial investment.